Regulatory Updates: Page 36

FDA: Avoid off-label use of some bone graft substitutes in young patients
By DrBicuspid.com staff writers
Clinicians should avoid routine off-label use of certain bone graft substitutes in patients younger than 18 years of age with bone disorders because of the risk for serious injury, according to the U.S. Food and Drug Administration (FDA).
January 22, 2015
Patterson to secure supply chain against gray-market products
By DrBicuspid.com staff writers
Patterson Companies announced that it is formalizing its efforts to promote supply chain integrity for its dental customers to help protect against potentially unsafe dental products entering the marketplace.
January 14, 2015
Ohio governor signs access-to-care bill
By DrBicuspid.com staff writers
Ohio Gov. John Kasich recently signed a bill into law to help improve access to dental care across the state.
January 13, 2015
Scynexis receives FDA fast-track designation for antifungal formulation
By DrBicuspid.com staff writers
Scynexis has been granted fast-track designation by the U.S. Food & Drug Administration (FDA) for the oral formulation of SCY-078, the company's novel antifungal product in development for the treatment of invasive Candidiasis, including candidemia and invasive aspergillosis.
January 11, 2015
Top 10 stories of 2014: Part 2
By Tony Edwards
With 2014 behind us, DrBicuspid.com reviews the most popular articles of last year. In part 2, we look at the top five stories, which included a dentist placing his own implant and a Small Smiles owner being excluded from Medicare and Medicaid.
January 4, 2015
2013 12 16 17 28 54 429 Top 10 200
U.K. dentists warned about counterfeit equipment
By DrBicuspid.com staff writers
U.K. dentists are being warned about fake dental equipment after officials reported a rise in counterfeit products being sold.
January 1, 2015
MiMedx comments on FDA draft guidance
By DrBicuspid.com staff writers
Regenerative medicine company MiMedx Group has commented on a draft guidance from the U.S. Food and Drug Administration (FDA) regarding cell- and tissue-based products.
December 30, 2014
Levin on the patient perspective; Oregon and SDF; regulatory issues in transactions
By Tony Edwards
December 28, 2014
Regulatory hot spots in dental transactions: Part 2
By Barton C. Walker, LauraLee Lawley, and John Saran
In this Second Opinion, a partner and two associates from healthcare law firm McGuireWoods continue their series on regulatory issues in dental transactions, focusing on dental service organizations (DSOs) and considerations such as noncompete clauses, billing procedures, and HIPAA compliance.
December 28, 2014
2013 12 23 15 23 25 385 Second Opinion 200
FDA's reclassification of SDF as a fluoride could mean new treatment options
By Donna Domino
The Oregon dental board's resolution allowing dental auxiliaries to apply silver diamine fluoride (SDF), which followed the recent classification of SDF as a fluoride by the U.S. Food and Drug Administration, could mean new treatment options, especially for Medicaid beneficiaries.
December 25, 2014
2014 09 04 16 45 47 306 Tooth Caries 200
Aspen Dental to pay nearly $1M over deceptive advertising claims
By DrBicuspid.com staff writers
Dental chain Aspen Dental has agreed to pay $990,000 to settle allegations of deceptive advertising and marketing practices and also failing to give refunds to consumers for services not provided in Massachusetts, according to the state attorney general.
December 21, 2014
Denti-Cal not delivering for kids; Levin on production; potential DSO regulatory issues
By Tony Edwards
December 21, 2014
Previous Page
Page 36 of 74
Next Page